Nicholas Kian Mollanazar, M.D., M.B.A.

faculty photo
Assistant Professor of Clinical Dermatology
Co-Chair EMR committee , University of Pennsylvania
Informatics Specialist , University of Pennsylvania
Director of Patient Access, Dermatology, University of Pennsylvania
Invited Member, Health System Strategic Planning Committee , University of Pennsylvania
Department: Dermatology

Contact information
Hospital of the University of Pennsylvania
Perelman Center for Advanced Medicine
Department of Dermatology
3400 Civic Center Blvd. South
Philadelphia, PA 19104
Education:
BS (Neuroscience and Behavioral Biology)
Emory University, Atlanta, GA, 2010.
MBA (Master of Business Administration)
Temple University Fox School of Business, Philadelphia, PA, 2015.
MD (Doctor of Medicine)
Temple Univeristy School of Medicine, 2015.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I have a passion for improving patient access and innovating on our care delivery models. In Dermatology, I have increased the percentage of NPVs seen within 10 days, placing us in the top 10% nationally for academic dermatology centers. I am currently working on piloting asynchronous visits in dermatology and OBGYN. The goal of asynchronous visits is to further improve our access initiatives, by innovating on how and where we deliver care to our patients.

I additionally have worked closely with pharmacy in our department. I noticed many providers were prescribing topicals that are not formulary for our Medicaid patients. Pharmacy was doing prior authorizations for these medications, only to end in a denial and a request to prescribe a covered preferred topical. As such, I met with pharmacy, and we created a universal Medicaid protocol. This protocol allows for interchangeability of commonly prescribed dermatologic medications for our patients so that pharmacy can quickly and efficiently switch to covered alternatives. The end result was a drastic reduction in denied PAs and patients were able to receive treatments in record times. We further expanded the project so that patients were given the option to receive their medication via delivery, if they were unable to come in to pick them up. Furthermore, the program increased revenue for the health system, as the prescriptions tended to stay in house.

Selected Publications

Kwatra SG, Yosipovitch G, Mollanazar N, Stander S, Kim BS, Hong HC, Msihid J, Bansal A, O'Malley TJ, Bahloul D, Thomas RB: Dupilumab Improves Multiple Factors Impacting Quaility of Life in Adults With Prurigo Nodulras (LIBERTY-PN PRIME and PRIME2). CDA Annual Conference 2023 June 2023.

Florez A, Yosipovitch G, Kwatra SG, Mollanazar N, Stander S Satoh T, Laws E, Mannent LP, Mortensen E, Maloney J, Shi G, Bansal , Martincova R: Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From Two Phase 3 Trails (LIBERTY-PN PRIME and PRIME 2). Academia Espnola de Dermatologia y Venereologia (AEDV) May 2023.

Wachuku, C., Barrera, T., Jackson, T., Sow, Y., Mollanazar, N., & Taylor, S.C: Upadacitinib, after failure with Dupilumab, as a treatment for chronic pruritus secondary to Polycythemia Vera. JAAD Case Reports 35: 87-89, March 2023.

Kwatra SG, Yosipovitch G, Mollanazar N, Stander S, Kim BS, Msihid J, Bansal A, O'Malley TJ, Bahloul D, Thomas RB: Dupilumab Improves Multiple Factors Impacting Quaility of Life in Adults With Prurigo Nodulras (LIBERTY-PN PRIME and PRIME2). AAD Association Annual Meeting March 2023.

Kwatra SG, Yosipovitch G, Mollanazar N, Stander S, Kim BS, Msihid J, Bansal A, O'Malley TJ, Bahloul D, Thomas RB: Dupilumab Improves Multiple Factors Impacting Quaility of Life in Adults With Prurigo Nodulras (LIBERTY-PN PRIME and PRIME2). 81th Annual Meeting of the American Academy of Dermatology March 2023.

Yosipovitch G, Mollanazar N, Stander S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade, Staudinger H, Patel N, Yancopoulos GD, Weinreich DM, Wang S, Shi G, Bansal A, O'Malley JT: Dupilumab in adult patients with prurigo nodularis: results from two randomized phase 3 trails. Nature Medicine March 2023.

Sow, Y., Wachuku, C., Barrera, T., Jackson, T., Ayoade, K. O., Taylor, S., & Mollanazar, N: Palmer and Plantar Erythema: An Initial Presentation of Undifferentiated Connective Tissue Disease. JAAD Case Reports 35: 94-97, March 2023.

Yosipovitch G, Kwatra SG, Mollanazar N, Stander S Satoh T, Laws E, Mannent LP, Mortensen E, Maloney J, Shi G, Bansal A, Martincova R: Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From a 2nd Phase 3 Trails (LIBERTY-PN PRIME and PRIME2). 4th San Diego Dermatology Symposium February 2023.

Yosipovitch G, Mollanazar N, Stander S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade B, Wang S, Shi G, Patel K, Bansal A, O'Malley TJ: Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From a 2nd Phase 3 Trail (LIBERTY-PN PRIME) Hawaii Dermatology Seminar - 45th Annual February 2023.

Yosipovitch G, Mollanazar N, Stander S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade B, Wang S, Shi G, Bansal A, O'Malley TJ: Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From a 2nd Phase 3 Trail (LIBERTY-PN PRIME). Maui Derm Caribbean January 2023.

back to top
Last updated: 04/23/2024
The Trustees of the University of Pennsylvania